Open AccessEfficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK‐Wide Real‐World Dataset
Author(s) -
Djebbari Faouzi,
Rampotas Alexandros,
Vallance Grant,
Panitsas Fotios,
Basker Nanda,
Sangha Gina,
Salhan Beena,
Karim Farheen,
AlKaisi Firas,
Gudger Amy,
Ngu Loretta,
Poynton Matt,
Lam Ho Pui Jeff,
Morgan Lowri,
Yang Laura,
Young Jennifer,
Walker Mairi,
Tsagkaraki Ismini,
Anderson Laura,
Chauhan Saleena Rani,
Maddams Rebecca,
Soutar Richard,
Triantafillou Margarita,
Prideaux Steve,
Obeidalla Abubaker,
Bygrave Ceri,
Basu Supratik,
Ramasamy Karthik
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/hs9.0000000000000738
Subject(s) - pomalidomide , multiple myeloma , dexamethasone , medicine , bortezomib
Real‐world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma patients have not been reported. In this UK‐wide retrospective study, IsaPomDex outcomes were evaluated across 24 routine care cancer centers. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression‐free survival (PFS), duration of response (DOR) for patients who achieved an objective response (≥partial response [PR]), and adverse events (AEs). In a total cohort 107 patients, median follow up (interquartile range [IQR]) was 12.1 months (10.1–18.6 mo), median age (IQR) was 69 years (61–77). Median (IQR) Charlson Comorbidity Index (CCI) score was 3 (2–4); 43% had eGFR <60 mL/min. Median (IQR) number of prior therapies was 3 (3–3). Median (IQR) number of IsaPomDex cycles administered was 7 (3–13). ORR was 66.4%, with responses categorized as ≥ very good partial response: 31.8%, PR: 34.6%, stable disease: 15.9%, progressive disease: 15%, and unknown 2.8%. Median PFS was 10.9 months. Median DOR was 10.3 months. There was no statistical difference in median PFS by age (<65: 10.2 versus 65–74 13.2 versus ≥75: 8.5 mo, log‐rank P = 0.4157), by CCI score (<4: 10.2 mo versus ≥4: 13.2, log‐rank P = 0.6531), but inferior PFS was observed with renal impairment (≥60: 13.2 versus <60: 7.9 mo, log‐rank P = 0.0408). Median OS was 18.8 months. After a median of 4 cycles, any grade AEs were experienced by 87.9% of patients. The most common ≥G3 AEs were neutropenia (45.8%), infections (18.7%), and thrombocytopenia (14%). Our UK‐wide IsaPomDex study demonstrated encouraging efficacy outcomes in the real world, comparable to ICARIA‐MM trial.